Communications
News & Press Release
-
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 toScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to2025.03.26
-
[BioRxiv]Astrocytic MAOB-GABA axis as a molecular brake on repair following spinal cord injuryNeuroregeneration and remyelination rarely occur in the adult mammalian brain and spinal cord following central nervous system (CNS) injury. The glial scar has been proposed as a major contributor to this failure in the regenerative process. However, its2025.02.27
-
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to2025.01.07
-
Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation2024.12.17
-
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 20252024.12.16
Notice
-
Neurobiogen exhibit booth at '2024 BIO International Convention'.Neurobiogen exhibit booth at '2024 BIO International Convention'. June 3-6, 2024, San Diego USA Booth exhibition No. : #36532024.05.29
-
Neurobiogen and Medica Korea exhibit booth together at '2023 BIO International Convention'.Neurobiogen and Medica Korea exhibit booth together at '2023 BIO International Convention'. June 5-8, 2023, Boston USA Booth exhibition No. : 24642023.05.09